ESTRO 2024 - Abstract Book

S809

Clinical - CNS

ESTRO 2024

6. Champeaux-Depond C, Weller J. Outcome After Protontherapy for Progression or Recurrence of Surgically Treated Meningioma. Brain Tumor Res Treat. 2021 Oct;9(2):46-57.

7. Krcek R, Leiser D, García-Marqueta M, Bolsi A, Weber DC. Long Term Outcome and Quality of Life of Intracranial Meningioma Patients Treated with Pencil Beam Scanning Proton Therapy. Cancers (Basel). 2023 Jun 7;15(12):3099.

8. Maas SLN, Sievers P, Weber DC, Weller M, van den Bent MJ, Mair MJ, Kros JM, Carparrotti F, von Deimling A, Salvador VF, Peerdeman SM, Casas-Martin J, Gorlia T, Sahm F, Preusser M. Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042-26042. Acta Neuropathol. 2023 Oct 19.

9. Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021 Nov 2;23(11):1821-1834.

10. Rombi B, Ruggi A, Sardi I, et al. Proton therapy: A therapeutic opportunity for aggressive pediatric meningioma. Pediatr Blood Cancer. 2021 May;68(5): e28919.

981

Digital Poster

High-dose proton therapy provides valuable outcomes in intracranial atypical meningiomas

Elisa Deraco 1,2 , Daniele Scartoni 1 , Giuseppe Della Gala 2 , Miriam Santoro 2 , Federica Medici 2 , Erika Galietta 2 , Stefano Lorentini 1 , Marco Cianchetti 1 , Silvia Cammelli 2 , Alessio Morganti 2 , Dante Amelio 1 1 Centro di Protonterapia, Azienda Provinciale per i Servizi Sanitari Trento, Trento, Italy. 2 Radioterapia, Azienda Ospedaliero-Universitaria Bologna, Bologna, Italy

Purpose/Objective:

To report clinical outcomes of high-dose active beam scanning proton therapy (PT) for intra-cranial atypical meningiomas (AM). To the best of our knolowdge this is the largest series of patients (pts) treated with PT for AM.

Material/Methods:

Forty-eight pts with AM were treated with PT between April 2015 and June 2023. Median age was 56 years (range, 19-82) while KPS ranged between 70 and 100 (median 90); 29 were female (60%), and 19 were male (40%). All pts had histologically proven World Health Organization (WHO) Grade II tumors. In 21 pts tumor was located in the skull base, while in 27 tumor location was in other intra-cranial sites. All tumors were complex in shape or in close proximity/abutting to organs at risk. All pts received PT for residual or progressive lesions after surgery. None of the pts received PT as re-irradiation. Dose prescription was 60 GyRBE (RBE: relative biologic effectiveness) in 30 fractions (2 GyRBE per fraction). Treatment planning was based on morphological magnetic resonance imaging (MRI) with contrast enhancement medium administration and 68-Ga-DOTATOC-PET. The gross tumor volume (GTV)